{"id":"yyc506","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, YYC506 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"YYC506 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:55:01.034Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT04874142","phase":"PHASE1","title":"Phase 1 to Evaluate the Safety and Pharmacokinetic Durg-drug Interaction of YYC506-T and YYC506-A","status":"COMPLETED","sponsor":"Yooyoung Pharmaceutical Co., Ltd.","startDate":"2019-11-20","conditions":"Dyslipidemias","enrollment":48},{"nctId":"NCT04874129","phase":"PHASE1","title":"Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506","status":"UNKNOWN","sponsor":"Yooyoung Pharmaceutical Co., Ltd.","startDate":"2021-01-07","conditions":"Dyslipidemias","enrollment":60},{"nctId":"NCT04858308","phase":"PHASE3","title":"Phase 3 Trial to Evaluate the Efficacy and Safety of YYC506.","status":"UNKNOWN","sponsor":"Yooyoung Pharmaceutical Co., Ltd.","startDate":"2021-01-29","conditions":"Dyslipidemias","enrollment":554}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"YYC506","genericName":"YYC506","companyName":"Yooyoung Pharmaceutical Co., Ltd.","companyId":"yooyoung-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"YYC506 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}